Holistic Health in LA's Chinatown The Corsair Diep speaks about a patient she saw who had stage four lung cancer. The doctors had given up on him and given him six months to live, said Diep. ...
What the Tumour Board says... Sakaal Times Cancer treatment may include chemotherapy (drugs), radiation therapy, surgery or a combination of these treatments. A medical oncologist is a physician who ...
Astellas Meets Antitrust Mark In OSI Attempt PharmaLive (press release) (subscription) OSI focuses on treatments for cancer, diabetes and obesity. It receives most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells ...
Astellas Meets Antitrust Mark In OSI Attempt PharmaLive.com (press release) OSI focuses on treatments for cancer, diabetes and obesity. It receives most of its revenue from the lung and pancreatic cancer drug Tarceva, which it sells ...
EU Panel Backs Marketing Authorization For Nivestim FOXBusiness ... with locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of standard platinum-based first-line chemotherapy. ...
OSI reports European recommendation on Tarceva Investor's Business Daily The Food and Drug Administration is expected to make a decision on the advanced lung cancer indication by April 18. Roche is OSI's partner on the drug, ...
Drug Combo Meets NSCLC Milestone MedPage Today The study compared both forms of the drug, in combination with carboplatin, for first-line treatment of patients with advanced non-small cell lung cancer. ...
EU Panel Backs Marketing Authorization For Nivestim NASDAQ ... locally advanced or metastatic non-small cell lung cancer with stable disease after four cycles of standard platinum- based first-line chemotherapy. ...
Treatment important tool in cancer fight News-Leader.com My wife has undergone this type of radiation therapy for lung cancer at the Hulston Center. This was the only course of action open in her case due to COPD. ...
UPDATE 1-Astellas substitutes two nominees to OSI board Reuters India LOS ANGELES, March 19 (Reuters) - Japan's Astellas Pharma Inc (4503.T: Quote, Profile, Research), which is pursuing a $3.5 billion hostile takeover of OSI ...
